Cyclic Peptidomimetics for Melanocortin Receptor Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current melanocortin receptor-specific peptides face limitations such as enzymatic degradation, short circulation half-life, limited bioavailability, and inadequate efficacy, which hinder their clinical application despite their potential in treating various diseases and conditions.
Innovation Solution
Development of peptidomimetics with specific structures that include amino acid surrogates and cyclic bridges, enhancing resistance to enzymatic degradation, bioavailability, and efficacy, while allowing for selective binding to melanocortin receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If peptide-based compounds are used for melanocortin receptor specificity, then high receptor specificity is achieved, but enzymatic degradation occurs and circulation half-life is short
Solution Approach 1:
The patent modifies the chemical structure of peptide-based compounds by introducing non-natural amino acids, cyclic bridges, and peptidomimetic modifications to change the chemical parameters of the molecule. These structural changes reduce enzymatic recognition and degradation while preserving receptor binding specificity, thereby resolving the contradiction between specificity and degradation resistance
Solution Approach 2:
The invention creates composite molecular structures combining natural amino acid sequences with synthetic peptidomimetic elements and cyclic bridge structures. This composite approach integrates the receptor-specific binding properties of natural peptides with the enzymatic stability of synthetic modifications, achieving both high specificity and degradation resistance
2Measurement precision
If peptide-based compounds are used for melanocortin receptor specificity, then high receptor specificity is achieved, but bioavailability is limited
Solution Approach 1:
The patent alters the physicochemical parameters of peptide compounds through peptidomimetic modifications and cyclic bridge formation, which improve membrane permeability and reduce first-pass metabolism. These parameter changes enhance bioavailability while maintaining receptor specificity through preserved binding epitopes
3Measurement precision
If peptide-based compounds are used for melanocortin receptor specificity, then high receptor specificity is achieved, but duration of effect is short
Solution Approach 1:
The invention modifies the pharmacokinetic parameters of peptide compounds by introducing cyclic structures and peptidomimetic elements that resist enzymatic degradation. These structural changes prolong the circulation half-life and extend the duration of receptor activation, resolving the contradiction between specificity and duration of effect
Data Source
AI summary
Linear and cyclic peptidomimetics which bind to one or more melanocortin receptors are provided, which peptidomimetics include at least one ring-constrained amino acid surrogate of formula I:where R1, R2, R3, R4, R5, R6, R7, R8, and y are as defined in the specification, together with methods for synthesizing ring-constrained amino acid surrogates of formula I and peptidomimetics incorporating the same, and methods of use of peptidomimetics in the treatment of various diseases, syndromes and conditions.